The objective of this study was to develop a quantitative model to delineate the net efficacy of taspoglutide on body weight (WT) loss from the response of placebo in type 2 diabetes patients, and further find pharmacodynamic potency of taspoglutide for half of maximum reduction response of ...
However, head-to-head placebo-controlled trials often are not feasible; they are expensive, time-consuming, and unethical if guidelines for a pharmaceutical intervention already exist [4]. Adjusted indirect comparison of randomized controlled trials has become an increasingly accepted method for ...
- Cost Per Placebo Adjusted Response of Golimumab, Adalimumab, and Etanercept in Patients with Active Ankylosing SpondylitisChenglong Han
Zhang ZW. Covariate-adjusted putative placebo analysis in active-controlled clinical trials. Stat Biopharmaceutical Res. 2009;1:279-90.Zhang Z. Covariate-adjusted putative placebo analysis in active-controlled clinical trials. Statistics in Biopharmaceutical Research 2009; 1:279-290....
Risk of HIV-1 infection (vaccine vs placebo), adjusted for herpes simplex virus 2 status at Phambili enrollment, within subgroups.Zoe, MoodieBarbara, MetchLindaGail, BekkerGavin, ChurchyardMaphoshane, NchabelengKoleka, MlisanaFatima, Laher
quality‐adjusted time without symptoms of progression or toxicity (Q‐TWiST)regorafenibIn a placebo‐controlled, randomized phase 2 trial (ClinicalTrials.govidentifier NCT01900743), regorafenib improved progression‐free survival (PFS) for patients with doxorubicin‐pretreated advanced nonadipocytic sarcoma...
Estimated Covariate-Adjusted HRs of HIV-1 Infection (Vaccine vs Placebo) Based on Step, Phambili and HVTN505 Combined.Yunda HuangDean FollmannMartha NasonLily ZhangYing HuangDevan V. MehrotraZoe MoodieBarbara MetchHolly JanesMichael C. Keefer
142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trialdoi:10.1016/j.annonc.2020.03.243G. Jerusalem...
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA psychiatry 73 (8), 779-788.Storch EA, Wilhelm S, Sprich S, Henin A, Micco J, Small BJ, et al. Efficacy of ...